{"id":"xg-102","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, I do not have information on the specific mechanism of action of XG-102.","oneSentence":"XG-102 is a small molecule that targets the [insert target here, if known].","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:41:10.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02561091","phase":"PHASE3","title":"AM-111 in the Treatment of Acute Inner Ear Hearing Loss","status":"COMPLETED","sponsor":"Auris Medical AG","startDate":"2015-11","conditions":"Hearing Loss","enrollment":256},{"nctId":"NCT02809118","phase":"PHASE3","title":"Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment","status":"TERMINATED","sponsor":"Auris Medical, Inc.","startDate":"2016-06","conditions":"Hearing Loss, Idiopathic Sudden Sensorineural","enrollment":56},{"nctId":"NCT02508337","phase":"PHASE3","title":"Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain","status":"COMPLETED","sponsor":"Xigen SA","startDate":"2015-07","conditions":"Inflammation, Pain, Cataract","enrollment":309},{"nctId":"NCT02235272","phase":"PHASE3","title":"Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation","status":"COMPLETED","sponsor":"Xigen SA","startDate":"2014-09","conditions":"Inflammation, Pain, Cataract","enrollment":339},{"nctId":"NCT00802425","phase":"PHASE2","title":"Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss","status":"COMPLETED","sponsor":"Auris Medical AG","startDate":"2008-12","conditions":"Hearing Loss","enrollment":210},{"nctId":"NCT01570205","phase":"PHASE1","title":"Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers","status":"COMPLETED","sponsor":"Xigen SA","startDate":"2011-07","conditions":"Inflammation","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"XG-102","genericName":"XG-102","companyName":"Xigen SA","companyId":"xigen-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}